Board of Directors

 

Rupert Lywood, Chairman

Rupert is a Chartered Accountant who qualified with Robson Rhodes. Latterly he specialised in structured finance and venture capital. Rupert has spent the last 25 years founding and building businesses in the energy, information, finance, medical, and media sectors – including co-founding and chairing a multi-billion European energy business which he sold to International Power in 2007. He remains active in all these sectors and in addition is currently focused on creating and delivering literacy programs in both the Developed and Developing World.

 

Stuart Lawson, Finance Director

Stuart is CEO of the private investment group headed by Animatrix Capital LLP, which holds a broad range of investments with the core focus being early stage medical research. Stuart serves as CFO of group members Loxbridge Research LLP, Premaitha Health Ltd and Agalimmune Ltd. He qualified as a Chartered Accountant before working as a Manager at KPMG. He then worked as a Finance Director before moving to and becoming Group CFO and European MD with a LSE fully quoted manufacturing company; during his time he led them through 16 Global acquisitions. Stuart is also a Trustee for the children’s charity, The Safepoint Trust, and serves as Chairman of a Mergers & Acquisitions Company based in Istanbul.

 

Peter Motteram, Chief Operating Officer

Peter has extensive experience in all types of clinical trials, having held senior positions at Quintiles and then at ClinTrials Research, where he had full responsibility for all clinical research services outside of the Americas. For the last 25 years Peter has been providing consulting services to pharmaceutical, biotechnology and medical device companies for the design and management of their clinical trials programmes.  Peter has supported trials both inside and outside UK, including in oncology and GI disease. Peter holds an M.Sc. in Clinical Biochemistry for University of London

 


Rachel Craven, Chief Scientific Officer

Rachel has over 20 years’ research experience in the life science sector, largely focussing on the discovery and validation of disease biomarkers. She joins Origin from Biosignatures Ltd where she set up a lab generating high quality gel-based proteomics data for the development of molecular diagnostic tests. Prior to that she worked in the academic sector, most recently as an Associate Scientist/ Technical Specialist at the University of Leeds. Rachel has BA in Biochemistry from the University of Oxford and a PhD from the University of Manchester.

 

 

Dr. Colin Ferrett, Medical Director

Colin is a consultant radiologist at Oxford University Hospital, having trained at Queen’s University, Belfast, UC San Diego and UC Stanford in medicine and radiology. He is a co-inventor of the OriCol™ balloon and founder of Origin Sciences. Involved in diagnostics, staging and research of CRC for 20 years, he is the PI of the recent successful trial. He has collected samples from several hundred patients with suspected colorectal cancer.

 

Per Aniansson, Non-Executive

Per Aniansson is currently an Investment Director at Fouriertransform AB, a Swedish Venture Capital/Private Equity company. He holds an MSc Engineering Physics from Chalmers University of Technology and an MBA from INSEAD. Prior to joining Fouriertransform Mr Aniansson gained experience in venture capital investments and other major investments from positions with Industrivärden, Siemens and Innovationskapital. Mr Aniansson was also a Management consultant with Accenture and Arthur D Little, mainly with a focus in the Pharma and Medtech business. He is on the board of a number of technology companies of which two are in the UK, Origin Sciences Ltd and Star Syringe Ltd.

 

Neil Laycock, Non-Executive

Neil joined Origin in December 2017. Neil is an accomplished leader in the health and technology sector, having previously been the CEO of the Internet Service Provider PlusNet and latterly the MD of www.patient.info (the UK’s largest private free online health resource that receives over 2 million unique hits per day) Neil was also the MD of EMIS Ltd (the largest UK software vendor in primary care hosting over 39million patient records)

 

Graham Griffiths Non-Executive Director

Graham qualified as a solicitor in 2005, before moving to co-found technology company MET that was subsequently sold to a group of private investors. He was an investment fund manager at Matrix Securities and for 9 years contributed across the portfolio of life sciences companies within the Animatrix Capital group. Graham’s focus was on developing early stage products and companies targeting the diagnosis and treatment of cancer and infectious diseases. Graham holds a BA Hons degree in Law with French from Newcastle University.

Now as a Non-Executive Director of Origin Sciences he mainly is involved in developing in vitro diagnostic tests to detect colorectal cancer (in a screening population) and inflammatory bowel disease, by analysis of human DNA, the microbiome and proteins. Commercialisation of OriCol medical device for sampling the gut mucosa.